From the Journals

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • By

  • February 17, 2026

  • 3 min

Share

  • 1

    Roche's fenebrutinib met primary endpoint in PPMS trial vs OCREVUS.

  • 2

    Study showed non-inferiority in reducing disability progression.

  • 3

    Fenebrutinib demonstrated 12% lower risk of disability progression.

  • 4

    Effects notable for upper limb function, crucial for independence.

  • 5

    Similar safety profiles; mild liver enzyme elevations with fenebrutinib.

  • 6

    Study followed 985 adults for at least 120 weeks.

  • 7

    Regulatory submissions planned after additional study results.

Original Source(s)

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • February 17, 2026

  • 3 min

Related Content

High Dose Vitamin D May Reduce MS Activity

Vitamin D significantly reduced disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis in the D-Lay MS trial.

Can HIIT Improve Symptoms Among Patients with MS?

A recent study looked at the effects of high-intensity interval training (HIIT) in bone and lipid metabolism markers as well as neuromotor abilities in patients with multiple sclerosis.

Diagnosing, Treating, and Preventing Multiple Sclerosis: Marcus Institute Gold Standard Center

Marcus Neuroscience Institute, established at Boca Raton Regional Hospital, has been a leader in neurological research and advanced therapies for years, bringing a personalized approach to treatment

  • by

  • April 5, 2024

  • 12 min